Tag: licensing
-
Carb-X Funds Vaccine Against Resistant Staph Infections
An international consortium is funding a vaccine to prevent increasingly resistant Staphylococcus aureus infections found in health care facilities.
-
Multiple Solid-Tumor Immunotherapy Trial Underway
A clinical trial is underway testing an immunotherapy for several types of stubborn solid tumor cancer, based on research in university labs.
-
Immune Response Shown in Alzheimer’s Vaccine
Results from a clinical trial show an experimental vaccine produces antibodies for breaking up harmful brain deposits in people with early Alzheimer’s disease.
-
AbbVie Licenses Engineered Crispr Cell Process
Drug maker AbbVie is acquiring a technology using the gene-editing process Crispr to produce new off-the-shelf engineered T-cells as disease therapies.
-
Cancer Immunotherapy Adapted for HIV
A biotechnology company is adapting and licensing its immunotherapy process, originally designed for cancer, as a cure for HIV infections.
-
Crispr Heart Disease Biotech Raises $94M in New Funds
A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round.
-
Universities Form Joint Engineering Patent Pool
A group of 15 American universities are putting part of their engineering patents into a common licensing pool for commercial development.
-
Biotech Licenses mRNA Technology for Aging
A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging.
-
Drug Maker Gains Access to Hidden Protein Immunotherapies
Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells.
-
Drug Price Disruptor Biotech Raises $500M in New Funds
A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round.